We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Walgreens (WBA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Read MoreHide Full Article
Walgreens Boots Alliance (WBA - Free Report) reported $36.71 billion in revenue for the quarter ended November 2023, representing a year-over-year increase of 10%. EPS of $0.66 for the same period compares to $1.16 a year ago.
The reported revenue represents a surprise of +5.10% over the Zacks Consensus Estimate of $34.92 billion. With the consensus EPS estimate being $0.63, the EPS surprise was +4.76%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Walgreens performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Number of locations at period end: 8,631 versus the two-analyst average estimate of 8,684.
Comparable sales - U.S. Retail Pharmacy - Pharmacy: 13.1% versus 0.4% estimated by two analysts on average.
Revenues- U.S. Healthcare: $1.93 billion versus $2.03 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +95.3% change.
Revenues- International: $5.83 billion compared to the $5.38 billion average estimate based on five analysts. The reported number represents a change of +12.4% year over year.
Revenues- U.S. Retail Pharmacy: $28.94 billion versus $27.44 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +6.4% change.
Revenues- U.S. Retail Pharmacy- Retail: $6.56 billion versus the three-analyst average estimate of $6.95 billion.
Revenues- U.S. Retail Pharmacy- Pharmacy: $22.38 billion versus the three-analyst average estimate of $20.61 billion.
Revenues- International - Wholesale: $2.97 billion compared to the $2.72 billion average estimate based on two analysts.
Revenues- International - Pharmacy: $926 million versus $885.42 million estimated by two analysts on average.
Revenues- International - Retail: $1.93 billion compared to the $1.73 billion average estimate based on two analysts.
Adjusted operating income (loss)- U.S. Retail Pharmacy: $694 million compared to the $644.18 million average estimate based on three analysts.
Adjusted operating income (loss)- U.S. Healthcare: -$96 million versus the three-analyst average estimate of -$87.85 million.
Shares of Walgreens have returned +19.6% over the past month versus the Zacks S&P 500 composite's +2.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Walgreens (WBA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Walgreens Boots Alliance (WBA - Free Report) reported $36.71 billion in revenue for the quarter ended November 2023, representing a year-over-year increase of 10%. EPS of $0.66 for the same period compares to $1.16 a year ago.
The reported revenue represents a surprise of +5.10% over the Zacks Consensus Estimate of $34.92 billion. With the consensus EPS estimate being $0.63, the EPS surprise was +4.76%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Walgreens performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Number of locations at period end: 8,631 versus the two-analyst average estimate of 8,684.
- Comparable sales - U.S. Retail Pharmacy - Pharmacy: 13.1% versus 0.4% estimated by two analysts on average.
- Revenues- U.S. Healthcare: $1.93 billion versus $2.03 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +95.3% change.
- Revenues- International: $5.83 billion compared to the $5.38 billion average estimate based on five analysts. The reported number represents a change of +12.4% year over year.
- Revenues- U.S. Retail Pharmacy: $28.94 billion versus $27.44 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +6.4% change.
- Revenues- U.S. Retail Pharmacy- Retail: $6.56 billion versus the three-analyst average estimate of $6.95 billion.
- Revenues- U.S. Retail Pharmacy- Pharmacy: $22.38 billion versus the three-analyst average estimate of $20.61 billion.
- Revenues- International - Wholesale: $2.97 billion compared to the $2.72 billion average estimate based on two analysts.
- Revenues- International - Pharmacy: $926 million versus $885.42 million estimated by two analysts on average.
- Revenues- International - Retail: $1.93 billion compared to the $1.73 billion average estimate based on two analysts.
- Adjusted operating income (loss)- U.S. Retail Pharmacy: $694 million compared to the $644.18 million average estimate based on three analysts.
- Adjusted operating income (loss)- U.S. Healthcare: -$96 million versus the three-analyst average estimate of -$87.85 million.
View all Key Company Metrics for Walgreens here>>>Shares of Walgreens have returned +19.6% over the past month versus the Zacks S&P 500 composite's +2.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.